Edition:
United Kingdom

Stemline Therapeutics Inc (STML.OQ)

STML.OQ on NASDAQ Stock Exchange Capital Market

15.54USD
4:54pm BST
Change (% chg)

$0.56 (+3.74%)
Prev Close
$14.98
Open
$15.07
Day's High
$15.54
Day's Low
$15.07
Volume
11,199
Avg. Vol
55,849
52-wk High
$20.55
52-wk Low
$10.25

Chart for

About

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the... (more)

Overall

Beta: -0.12
Market Cap(Mil.): $302.10
Shares Outstanding(Mil.): 25.28
Dividend: --
Yield (%): --

Financials

  STML.OQ Industry Sector
P/E (TTM): -- 86.20 32.69
EPS (TTM): -2.44 -- --
ROI: -65.15 0.73 14.32
ROE: -65.34 1.82 16.04

BRIEF-Stemline Therapeutics Reports Q1 Loss Per Share $0.69

* STEMLINE THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

09 May 2018

Competitors

  Price Chg
Astellas Pharma Inc (4503.T) ¥1,856 +27.50
Eisai Co., Ltd (4523.T) ¥10,460 +160.00
Sumitomo Dainippon Pharma Co Ltd (4506.T) ¥2,635 +73.00
Pfizer Inc. (PFE.N) $43.82 +0.70
Novartis AG (NOVN.S) CHF84.08 +1.62
Merck & Co., Inc. (MRK.N) $71.01 +1.55
Roche Holding Ltd. (ROG.S) CHF240.55 +5.30
Roche Holding Ltd. (RO.S) CHF241.00 +4.40
Sanofi SA (SASY.PA) €76.41 +1.12
GlaxoSmithKline plc (GSK.L) 1,486.00 +22.40

Earnings vs. Estimates